Ensysce Biosciences, Inc. SEC filings ENSC
Ensysce Biosciences, Inc. has 547 filings in SEC EDGAR's recent list, going back to Oct 3, 2017. Its latest annual report, Form 10-K, was filed on Mar 30, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 13, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Nov 4, 2026 (officer or director change). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| PRE 14A | Preliminary proxy statement | Oct 30, 2026 | Oct 30, 2026 |
| DEFA14A | Additional proxy material | Dec 16, 2025 | — |
| DEF 14A | Proxy statement | Dec 2, 2025 | Dec 2, 2025 |
| PRE 14A | Preliminary proxy statement | Nov 21, 2025 | Nov 21, 2025 |
| DEFA14A | Additional proxy material | Nov 19, 2024 | — |
| DEFA14A | Additional proxy material | Oct 18, 2024 | — |
| DEF 14A | Proxy statement | Oct 18, 2024 | Oct 17, 2024 |
| PRE 14A | Preliminary proxy statement | Oct 7, 2024 | Oct 7, 2024 |
| DEFA14A | Additional proxy material | Dec 19, 2023 | — |
| DEFA14A | Additional proxy material | Nov 13, 2023 | — |
| DEF 14A | Proxy statement | Nov 13, 2023 | Nov 9, 2023 |
| PRE 14A | Preliminary proxy statement | Oct 30, 2023 | Oct 30, 2023 |
| DEFA14A | Additional proxy material | Jul 14, 2023 | — |
| DEF 14A | Proxy statement | Jul 14, 2023 | Jul 13, 2023 |
| DEF 14A | Proxy statement | Feb 24, 2023 | Feb 23, 2023 |
| PRE 14A | Preliminary proxy statement | Feb 13, 2023 | Feb 13, 2023 |
| DEF 14A | Proxy statement | Jul 29, 2022 | Jul 29, 2022 |
| DEFA14A | Additional proxy material | Jul 29, 2022 | — |
| PRE 14A | Preliminary proxy statement | Jul 13, 2022 | Jul 12, 2022 |
| DEFA14A | Additional proxy material | Jun 21, 2022 | — |
| DEFA14A | Additional proxy material | May 6, 2022 | — |
| DEFA14A | Additional proxy material | May 2, 2022 | — |
| DEF 14A | Proxy statement | May 2, 2022 | May 2, 2022 |
| DEFA14A | Additional proxy material | Jan 18, 2022 | — |
| DEFA14A | Additional proxy material | Dec 27, 2021 | — |
| DEFA14A | Additional proxy material | Dec 17, 2021 | — |
| DEF 14A | Proxy statement | Dec 17, 2021 | Dec 17, 2021 |
| PRE 14A | Preliminary proxy statement | Dec 1, 2021 | Dec 1, 2021 |
| DEF 14A | Proxy statement | Nov 3, 2020 | Nov 24, 2020 |
| PRE 14A | Preliminary proxy statement | Oct 20, 2020 | Oct 19, 2020 |
| DEFA14A | Additional proxy material | Jun 24, 2020 | — |
| DEF 14A | Proxy statement | Jun 2, 2020 | Jun 23, 2020 |
| PRE 14A | Preliminary proxy statement | May 15, 2020 | May 14, 2020 |
| DEFA14A | Additional proxy material | Mar 25, 2020 | — |
| DEF 14A | Proxy statement | Mar 3, 2020 | Mar 26, 2020 |
| PRE 14A | Preliminary proxy statement | Feb 21, 2020 | Feb 21, 2020 |
| PREM14A | Filing | Jan 31, 2020 | Jan 31, 2020 |
| DEF 14A | Proxy statement | Oct 28, 2019 | Nov 26, 2019 |
| PRE 14A | Preliminary proxy statement | Oct 15, 2019 | Oct 15, 2019 |
| DEF 14A | Proxy statement | Nov 14, 2018 | Dec 14, 2018 |
Showing 40 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ENSC (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- La Jolla, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1716947
- Former names
- Leisure Acquisition Corp. (until Jun 30, 2021)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.